Status:

COMPLETED

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

Lead Sponsor:

Array BioPharma

Conditions:

Advanced Cancer

Pancreatic Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This is a 2-phase study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and gemcitabine. The study has 2 parts. In the first part of th...

Eligibility Criteria

Inclusion

  • Key Inclusion Criteria (Part 1):
  • Histologically or cytologically confirmed diagnosis of a solid tumor suitable for treatment with gemcitabine.
  • No more than 3 prior anticancer regimens for advanced disease.
  • Measurable or evaluable, nonmeasurable disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
  • Able to take and retain oral medications.
  • Additional criteria exist.
  • Key Exclusion Criteria (Part 1):
  • Uncontrolled or symptomatic brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must have been stable for at least 30 days).
  • Treatment with prior chemotherapy within 21 days of first dose of study drug.
  • Requiring IV alimentation.
  • Pregnancy or lactation.
  • Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C.
  • History of being unable to tolerate gemcitabine or any of its components.
  • Additional criteria exist.

Exclusion

    Key Trial Info

    Start Date :

    March 1 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 1 2011

    Estimated Enrollment :

    20 Patients enrolled

    Trial Details

    Trial ID

    NCT00862524

    Start Date

    March 1 2009

    End Date

    February 1 2011

    Last Update

    October 4 2012

    Active Locations (6)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (6 locations)

    1

    Pinnacle Oncology/Hematology

    Phoenix, Arizona, United States, 85258

    2

    Premiere Oncology

    Santa Monica, California, United States, 90404-2111

    3

    University of Colorado Health Sciences Center

    Aurora, Colorado, United States, 80045

    4

    Partners, Massachusetts General Hospital

    Boston, Massachusetts, United States, 02114